Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

Background & Aims: Glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies deliver histological benefit in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Multiple mechanisms may be important including weight loss, improved glycaemic control and putative direct...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Ahmad Moolla, Toryn Poolman, Nantia Othonos, Jiawen Dong, Kieran Smith, Thomas Cornfield, Sarah White, David W. Ray, Sofia Mouchti, Ferenc E. Mózes, Helena Thomaides-Brears, Stefan Neubauer, Jeremy F. Cobbold, Leanne Hodson, Jeremy W. Tomlinson
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-05-01
Serija:	JHEP Reports
Teme:	MASLD GLP-1 Liraglutide Weight loss
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2589555925000400
Oznake:	Označite Brez oznak, prvi označite!